Form 8-K - Current report:
SEC Accession No. 0000950170-21-000648
Filing Date
2021-08-02
Accepted
2021-08-02 16:10:10
Documents
15
Period of Report
2021-08-02
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rare-20210802.htm   iXBRL 8-K 44470
2 EX-99.1 rare-20210802ex99_1.htm EX-99.1 394493
3 GRAPHIC img152232010_1.jpg GRAPHIC 271622
4 GRAPHIC img152232010_0.jpg GRAPHIC 271622
  Complete submission text file 0000950170-21-000648.txt   1320036

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rare-20210802_pre.xml EX-101.PRE 9595
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rare-20210802_lab.xml EX-101.LAB 12936
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rare-20210802.xsd EX-101.SCH 2447
8 EXTRACTED XBRL INSTANCE DOCUMENT rare-20210802_htm.xml XML 4522
Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Filer) CIK: 0001515673 (see all company filings)

EIN.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36276 | Film No.: 211136143
SIC: 2834 Pharmaceutical Preparations